Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ESES and clinical CSWS/LKS defined by all of the following:~* SWI ≥50% during first hour of sleep~* Bilateral synchrony of discharges during sleep~* Clinical evidence of behavior and/or academic regression~* Daytime SWI ≤20%~Exclusion Criteria:~* Previous treatment with benzodiazepine or acetazolamide for Electrical Status Epilepticus in Sleep (ESES)~* Current treatment with carbamazepine, phenytoin, oxcarbazepine, phenobarbital, vigabatrin or lamotrigine~* Antiepileptic medication changes over the month prior to enrollment~* Epileptic encephalopathy other than CSWS/LKS~* Prior serious adverse reaction to benzodiazepines or acetazolamide~* Sulfa allergy~* Progressive underlying neurologic condition~* Frequent seizures that would prevent the patient from maintaining a stable dose of medications~* Female patient that has begun menses or is pregnant

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Diazepam (Type: ACTIVE_COMPARATOR): Diazepam 0.5 mg/kg (up to maximum 20 mg) by mouth nightly. Duration of therapy is 4 weeks.
- Acetazolamide (Type: EXPERIMENTAL): Acetazolamide 8-10 mg/kg (up to a maximum dose of 375 mg) by mouth (PO)divided twice daily X 1 week, then increased to 11-16 mg/kg (up to a maximum dose of 750 mg) by mouth divided twice daily thereafter. Duration of therapy is 4-8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).